Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a .
Yumanity Therapeutics IncApril 6, 2021 GMT
YTX-7739 demonstrates efficacy, including increased median overall survival, both as a single agent and in combination with temozolomide, the standard-of-care for GBM
Shared therapeutic target with Parkinson’s disease expands potential utility of
YTX-7739 to non-neurodegenerative diseases
SNO/NCI Joint Symposium: Targeting CNS Tumor Metabolism
BOSTON, April 06, 2021 (GLOBE NEWSWIRE) Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced results of a study that demonstrate